Login to Your Account

Corbus’ resunab shines in phase II systemic sclerosis trial, sending shares higher

By Michael Fitzhugh
Staff Writer

Monday, November 14, 2016

Corbus Pharmaceuticals Holdings Inc. reported that its sole candidate – resunab – added to SOC immunosuppressive drugs, out-performed a placebo with SOC during a phase II trial in patients with diffuse cutaneous systemic sclerosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription